PRICEFX
15.5.2019 11:02:11 CEST | Business Wire | Press release
Pricefx , the global leader in cloud pricing software, today announced on stage at its user conference Accelerate19 that subscribers of the company’s core SaaS product offerings will now receive full access to the entire platform feature set for no additional cost. This is possible now that Pricefx has completed its evolution to a platform provider and unified its integration and connectivity capabilities. Pricefx’s powerful enterprise-grade technology platform provides simple point-and-click configuration for back-end, front-end, primary and third-party intellectual property (IP) enablement.
By including the platform with core product subscriptions, Pricefx will further lower the total cost of ownership for its customers. Additionally, the platform’s simple access to a broad range of pricing IP and ready-made capabilities will accelerate customer time-to-value on the Pricefx investment.
“The evolution from discrete solutions to a full-featured platform creates a new benchmark for best-in-class cloud pricing,” said Gabriel Smith, chief evangelist at Pricefx. “We are delivering powerful and innovative new features that create a more connected, integrated and modular cloud-native platform -- and at no additional charge to customers. Organizations can now harness unprecedented power of the full Pricefx product suite delivered through an enterprise-scale platform that manages data, multi-system connectivity, and more, with the same fast, flexible and friendly SaaS approach the industry has come to expect from Pricefx.”
Previously, Pricefx offered IntegrationManager as separate product which connected Pricefx SaaS products with back-end data and services such as ERP and PLM systems. Pricefx also continued to build front-end systems integrations with leading providers and helped its partners develop focused and pricing-specific IP. Today, these capabilities have been unified inside a single platform free to customers of the company’s core SaaS products and to partners for the development, addition and distribution of its own IP.
The Pricefx platform will continue to provide and support all of the back-end connectivity and capabilities of IntegrationManager and will continue enabling connectivity with leading CRM systems and across the Pricefx suite of products. Now customers can more easily integrate Pricefx into their organization and leverage the full power of the platform.
The platform will now also enable customers to easily select and configure specific ready-made pricing IP – algorithms, data sets, guidance, templates, models and starter kits. Customers will be able to quickly establish connectivity to and distribute IP across their existing instance of Pricefx. Additional platform features include access to foundational services including master data management (MDM), workflow and dashboard capabilities.
Follow Pricefx
Blog: https://www.pricefx.com/site/blog/
Twitter: https://twitter.com/price_fx
LinkedIn: https://www.linkedin.com/company/price-f-x-/
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, easy to use, and flexibly adapt to any business need. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, to power pricing Insights, Definitions, and Realization. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005046/en/
Contact:
Media Contact: Cathy Summers Summers PR cathy@summers-pr.com +1 (415) 483-0840
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom